Commerzbank Aktiengesellschaft FI Makes New Investment in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Commerzbank Aktiengesellschaft FI purchased a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 4th quarter, HoldingsChannel reports. The fund purchased 2,041 shares of the medical equipment provider’s stock, valued at approximately $216,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of ZBH. Geode Capital Management LLC boosted its stake in Zimmer Biomet by 2.6% during the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock valued at $524,942,000 after buying an additional 125,852 shares in the last quarter. Van ECK Associates Corp boosted its position in shares of Zimmer Biomet by 5.9% during the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock valued at $417,814,000 after purchasing an additional 218,688 shares in the last quarter. Hotchkis & Wiley Capital Management LLC grew its stake in shares of Zimmer Biomet by 49.1% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock worth $189,161,000 after purchasing an additional 577,320 shares during the last quarter. Equity Investment Corp raised its holdings in shares of Zimmer Biomet by 57.2% in the 4th quarter. Equity Investment Corp now owns 1,021,062 shares of the medical equipment provider’s stock worth $107,855,000 after purchasing an additional 371,653 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in Zimmer Biomet by 0.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,006,217 shares of the medical equipment provider’s stock valued at $108,621,000 after purchasing an additional 4,388 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on ZBH shares. Truist Financial restated a “hold” rating and issued a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Raymond James decreased their target price on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Barclays dropped their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Monday, February 10th. Finally, Royal Bank of Canada reduced their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Trading Up 0.7 %

NYSE ZBH opened at $104.71 on Thursday. The company has a market capitalization of $20.84 billion, a PE ratio of 23.53, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The firm’s fifty day simple moving average is $105.57 and its 200-day simple moving average is $107.26.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the company posted $2.20 EPS. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.